Grifols soars 11% on report of Brookfield resuming takeover negotiations

Published 02/04/2025, 09:20
© Reuters

Investing.com -- Grifols (BME:GRLS) shares surged more than 11% on Wednesday following a report by El Confidencial that Canadian investment firm Brookfield has renewed takeover discussions with the Spanish pharmaceutical group.

The stock traded at 9.06 euros as of 08:19 GMT.

According to the report, Brookfield has reached out to the Grifols founding family and is weighing a new offer that could value the company at around 7 billion euros ($7.55 billion).

The fund is reportedly working with Morgan Stanley (NYSE:MS) on the potential bid.

Brookfield had previously made a non-binding proposal last November, valuing Grifols at 6.7 billion euros, but withdrew after the company’s leadership dismissed the offer as inadequate and advised shareholders not to sell.

After Capital Markets Day (CMD), Grifols “is in a superior cash and governance position and on track to realise strong growth,” Barclays (LON:BARC) analysts said.

The analysts believe that a potential take-private of Grifols could allow the new management team, in place since 2024, to focus more effectively on advancing the company’s turnaround strategy launched in September 2022.

They argue that operating outside the pressures of public market volatility would benefit the process.

At the time of Brookfield’s previous bid, Barclays had suggested a fair value for Grifols A shares in the range of €12 to €13, higher than the €10.5 per share offer that was rejected.

The investment bank also pointed out that the proposal had not accounted for the company’s requirement to offer the same price for both A (ordinary) and B (preferred) shares under its articles of association.

Barclays noted that investor feedback then indicated some shareholders were seeking up to €15 per share.

“We expect shares to react positively to the news that the long-term GRF value could be realised near-term, but warn against the return of media headline risk as we predict a return of articles focused on the potential progress of a deal,” analysts concluded.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.